ScripStock market volatility due to business interruptions caused by the novel coronavirus has brought most fundraising by public companies to a halt, but so far COVID-19 hasn’t slowed the flow of venture
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Jounce Gets $50m Up Front As
ScripItaly’s Zambon Co. SPA has paid an initial €140m to acquire the VC-backed German/US biotech, Breath Therapeutics Holding BV in a move that strengthens the specialty products pipeline of the mid-si
Generics BulletinCipla is entering the specialty respiratory segment by striking a definitive agreement with inhalation specialist Pulmatrix to develop and commercialize a proprietary formulation of the antifungal ag